OSE: share price rises on positive preclinical data

(CercleFinance.com) - OSE Immunotherapeutics shares rose on the Paris Bourse on Friday, following the biotech company's publication of positive preclinical data in chronic colitis.


OSE reports that yesterday it presented data on the combination of IL-7 with monoclonal antibodies in chronic colitis at the European Crohn's and Colitis Organization (ECCO) congress currently taking place in Berlin

The oral presentation showed that IL-7 prevented the inhibitory effect of IL-23 antagonists on the control of human Th17 T lymphocytes, the company points out.

At the same time, overexpression of IL-7R in the colon of patients with ulcerative colitis or Crohn's disease correlates with high IL-23 expression.

The combination of anti-IL-7R with an anti-IL-12/23 antibody was also shown to be well tolerated and synergistic in controlling the symptoms of chronic colitis in a preclinical model, reports OSE.

'The administration of this dual therapy has enabled complete remission to be achieved in preclinical models of chronic colitis, both biologically, histologically and physiologically', explain analysts at Allinvest Securities.

These new data underline the strong potential of OSE-127 in IBD (chronic inflammatory bowel disease)", emphasized the brokerage firm.

OSE Immunotherapeutics shares gained over 3% on Friday on the Paris Bourse in the wake of this news.

Copyright (c) 2025 CercleFinance.com. All rights reserved.